StockData

Septerna vs vTv Therapeutics

SEPN and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SEPN and VTVT compare

Septerna is the larger company, worth 26 times as much as vTv Therapeutics ($2.0B against $77.9M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 337% for Septerna).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.8% compared with −61.3% at Septerna.

vTv Therapeutics scores higher on the StockData Score (11 against 8 for Septerna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSEPNVTVT
Size and price
Market cap$2.0B$77.9M
Share price$42.60$19.69
Change, 1 year122%−36.5%
Change, 5 years–−65.3%
Beta (5Y)1.871.08
Employees13026
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score11
Performance score12 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S20.7×2.1× (better)
P/B4.6×1.1× (better)
FCF yield−3.9%–
Fair value$14.45$40.43
Margin of safety−195%51.3% (better)
Growth
Revenue growth (TTM)337%216600% (better)
Profitability
Operating margin−76.2%−29.8% (better)
Net margin−61.3%−20.8% (better)
FCF margin−80.6%–
Return on equity−14.4%−11.0% (better)
Financial health
Debt / equity0.000.00
Current ratio4.8411.19 (better)
Altman Z-score6.29 (better)0.51
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%40.6%
Held by insiders28.1%26.3%
Insider net buying, 12 months−$76.1M–
Short interest, % of float10.0%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.